SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.

Already have an account? Log in here
RETURN TO HOME
$0
Autologous, CAR-T, CD19

Celgene’s CVR Payment Vanishes As Liso-cel Is Not Approved Before Dec 31, 2020

Here is a brief preview of this blast: As of January 1, 2021, the FDA has not yet approved BMS’s CD19 CAR-T liso-cel, and BMS's press release today confirmed the termination of the Celgene CVR. Below, Celltelligence provides insights on the potential for litigation following liso-cel’s missed approval deadline for Celgene’s CVR shareholders.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.